For many patients with type 2 diabetes (T2D), insulin treatment will be required to control hyperglycemia and to reduce the risk of long-term vascular complications in patients with T2D. [1] [2] [3] [4] [5] Typically, this will involve the initiation of a basal or a biphasic insulin regimen, with some patients requiring multiple daily insulin injections with basal and prandial insulin.
However, insulin therapy is known to induce~4-to 9-kg weight gain in the first year of treatment. 6 Furthermore, recent evidence from randomized controlled trials (RCTs) and epidemiological and observational studies has questioned the long-term cardiovascular (CV) safety of insulin therapy. [7] [8] [9] [10] [11] [12] Conversely, the CV benefits of the glucagon like peptide-1 analogues (GLP-1RA), a novel injectable glucose-lowering therapy, with favorable effects on weight and low risks of hypoglycemia, are an active area of research (http://www.clinicaltrials.gov). Preclinical studies have already demonstrated the pleotropic effects of GLP-1RA on myocardium and vascular endothelium, 13, 14 and many clinical studies have reported improvement in surrogate markers of CV disease. 15 More recently, The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial showed that liraglutide, a GLP-1RA, is associated with significant reductions of CV events and death from CV causes. 16 Thus, because insulin therapy is known to be associated with weight gain and increased risk of hypoglycemia, adding a GLP-1RA to insulin therapy is an attractive option to lower HbA1c levels in overweight patients with T2D. 17 No comparative "real-world" metabolic outcome data of insulin versus insulin plus GLPRA are available, and further work is required to explore the CV effects of insulin compared with insulin plus GLP-1RA in overweight patients with T2D, who are at an inherent risk of developing CV disease.
The aim of the present study therefore was to determine the real-world composite CV and mortality outcomes in UK clinical practice among insulin-treated patients with T2D who received adjunctive treatment with a GLP-1RA compared with those who did not.
Methods

Study design and data sources
A retrospective cohort study was conducted using The Health Improvement Network (THIN)-a UK computerized longitudinal anonymized primary care database in which information is systematically entered by primary care physicians. With details of N10.5 million patients from about 532 general practices, it has been validated and shown to be demographically representative of the UK population in terms of demography, major conditions prevalence, and mortality rates. 18, 19 It has been validated by many studies and in our previous studies, used extensively to evaluate diabetes-related outcomes in routine clinical practice. 20 , 21 
Study population
We obtained data of all insulin users with T2D from the THIN database who were aged 18 and above, initiated insulin therapy (as dual, triple, or more therapy) between January 2006 and May 2014, and went on to have their insulin therapy intensified with either an add-on of GLP-1RA or not, independent of the use of other GLTs. We excluded participants who commenced GLP-1RA before insulin therapy and those with type 1 diabetes. From this main cohort, we excluded all patients with a prior history of CV events (stroke or acute myocardial infarction [AMI]) before or within 180 days after insulin initiation in a subgroup analysis on CV events.
Exposures and outcomes
Exposure
The main exposure was the initiation of any GLP-1RA or otherwise among insulin users. Insulin regimen can be ultra-short/short-acting, premixed or long-acting, whereas GLP-1RAs are exenatide, liraglutide, or lixinatide. The study was exposure based. Insulin users on dual, triple, or more therapies who went on to add GLP-1RA were at that point included and then compared with patients who did not have GLP-1RA as an add-on therapy.
From this stage, participants were followed up for a maximum of 5 years and were censored at the earliest of the following: discontinuation or substitution of GLP-1RA or insulin, loss to follow-up (transfer out of practice), first occurrence of any of the study outcomes, or at the end of the study after 5 years. This implies that if no records of prescriptions of GLP-RA or insulin were found after 1 year in the electronic records, such medication was considered stopped and the patient was censored at this point.
Outcome. In the main cohort, the primary outcomes were time to the risk of a 3-point composite event of major adverse cardiovascular event (MACE) which comprises all-cause mortality, nonfatal MI, and nonfatal stroke. The time to the risk of 2-point composite CV event (nonfatal MI or nonfatal stroke) was estimated in a subgroup of patients from the main cohort with no prior CV history. These outcomes and their dates of occurrence were identified by their appropriate Read Codes in the THIN database. The secondary outcomes were the mean changes in hemoglobin A1c (HbA1c; glycemic control) and weight between both treatment groups from baseline at 6, 12, 24, and 36 months.
Covariates
Important time-varying clinical baseline covariates were extracted and included in the data. These were fitted in our regression models to adjust for their confounding effects on the study outcome. These include baseline demographic parameters as age; gender; socioeconomic status (measured by the Townsend deprivation scores and ranked in quintiles); alcohol and smoking status; and clinical measures like body mass index (BMI), weight, height, and systolic (SBP) and diastolic blood pressure (DBP). Also, other important biochemical parameters such as baseline HbA1c, lipid profile, glomerular filtration rate (GFR), creatinine level, albumin-creatinine ratio (ACR), the use of other medications including GLTs; comorbidity status; the duration of diabetes treatment; and insulin use were included and adjusted for in our analyses.
Statistical analyses
We summarized baseline variables within the treatment groups (INS + GLP-1RA vs INS + non-GLP-1RA) using mean values and SD for continuous variables and frequencies (%) for categorical variables (Table I) . We therefore estimated the propensity score (PS) for treatment with GLP-1RA using logistic regression as the conditional probability of being treated with GLP-1RA with the baseline covariates as age, gender, socioeconomic status, alcohol and smoking status, BMI, weight, height, SBP, DBP, HbA1c, lipid profile, GFR, creatinine level, ACR, the use of other medications, comorbidity status, and the duration of diabetes treatment. We matched both treatment groups (GLP-1RA vs non-GLP-1RA) based on their estimated treatment probabilities, with the average treatment effect on the treated computed by 1:1 matching Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin (index date). TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SGLT2, sodium-glucose cotransporter-2 inhibitors; DPP4, dipeptidyl peptidase-4 inhibitors; LLT, lipid-lowering therapy; CHD, coronary heart disease; PAD, peripheral arterial disease. Standardized differences are the absolute difference in means or percentage divided by the standard deviation of the treated group. Resulting standardized difference after 1:1 matching based on average treatment effect on treated PS technique and robust variance estimation. ⁎ In the matched cohort, only DPP4 and PAD had statistically significant standardized difference at 0.10 level.
for each group at the nearest distance, measured by the estimated PS. The standardized differences between the treatment groups following adjustment with the PS and all the baseline variables were calculated using linear regression models with their P values determined. A difference N10% was considered significant. In the summary table (Table I) as well, the distribution of the covariates between the treatment groups in the PS matched group was also summarized.
Using the Kaplan-Meier survival estimate, we obtained the crude and adjusted 5-year estimates of survival functions for both treatment groups (INS + GLP-1RA vs INS + non-GLP-1RA). We calculated the absolute reduction in the probability of the incidence of the outcome within a 5-year follow-up from these survival functions. Also, we estimated the marginal hazard ratios to quantify the adjusted hazard of MACE and the incidence of mortality and CV events in the GLP-1RA group (treated group) compared with the non-GLP-1RA group. Having considered PS a prognostic covariate, it was included in the final Cox proportional hazards regression model. To test for violations of the proportional hazard, assumption of the Cox regression analysis was made by adding an interaction term of the predictor and log time and by analyzing the Schoenfeld residuals. We did not observe any violations of the proportional hazard assumption because both were found to be nonsignificant. We used maximum likelihood estimation to explore if there are any possible interactions between the treatment groups and the baseline variables which were included in the PS but found no interactions with any of the covariates.
Finally, we compared glycemic efficacy (measured by change in HbA1c from baseline at different follow-up timelines) and changes in weight and blood pressure (systolic and diastolic) between the 2 treatment groups using Student t test and linear regression while adjusting for significant baseline covariates. Ethical approval for this study was obtained by The South-East Research Ethics Committee.
Subgroup and sensitivity analyses
We compared the study outcomes between the full data and PS-matched population to compare the confounding effect the selection bias could have on the full cohort. Also, we did further subgroup analyses to estimate the hazards of the components of CV events-nonfatal stroke and MI in patients with no prior history of any CV event. We also estimated the hazard of MACE, all-cause mortality, and CV events in the subtypes of GLP-1RA identified in the data set (liraglutide, exenatide, and lixinatide) using the non-GLP-1RA group as the comparator.
Statistical significance was put at a P level of .05, and to avoid the probability of type II error, we powered the study to 0.9 with a minimum sample size of 400 in each arm estimated to be adequate to detect a true difference of 0.1 between the 2 treatment groups at 5% significance level. In the regression models and all other analyses, the point estimates were computed, with 95% CI, at the conventional statistical significance level of .05. We used multiple imputations using the chained equation model to account for any missing data among covariates. All analyses were conducted using Stata Software, version 14.
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Results
Cases and total follow-up
A total of 18,227 adults with insulin-treated T2D whose standard care with insulin was either intensified with GLP-RA (1943) or not (16, 284) were selected from the THIN database. Furthermore, as shown in Figure 1 , after PS matching in both cohorts, the total population was reduced to 3,586 (n = 1,793 in each arm) in the main cohort. The mean follow-up duration was 3.2 (SD: 3.07) years, representing a total follow-up period of 12,681.9 person-years. Table I is a summary of the distribution of the baseline characteristics of the study participants between the treatment groups in the full and matched cohorts, respectively. The overall mean age was 62.7 (13.8) years. A slightly higher proportion (53.2%) was composed of men, whereas the mean baseline HbA1c level was 8.6% (1.8%). Furthermore, the overall baseline weight and BMI were 90.8 (18.7) kg and 32.4 (6.9) kg/m 2 , respectively. Significant differences in the distribution of the baseline variables between the treatment groups in the full cohort were observed. These were in baseline HbA1c, BMI, weight, diabetes duration, and current alcohol intake, among others, which were higher in the GLP-1RA group, whereas age and SBP were significantly higher in the non-GLP-1RA group. Following one-on-one PS matching, 1,793 patients were matched to each other in both treatment groups, and no differences in baseline variables were noted. Table I shows the distribution of the baseline variables between both treatment groups with these baseline variables compared between the full and matched cohort of patients, with their standardized differences shown.
Patients' characteristics
Crude event rates
Composite outcome (MACE). The probability of survival for a 3-point composite MACE was similar (99%) in both treatment groups after 1 year but was significantly reduced at 5 years to 96% and 93% in the GLP-1RA and non-GLP-1RA groups, respectively (log-rank test P value = .0055). The unadjusted crude incidence rate was 12.1 per 1,000 person-years (9.1 vs 14.7), signifying a total of 153 events (55 vs 98) in the GLP-1RA versus non-GLP-1RA groups, respectively (Table II) .
Mortality. Also in the main cohort, the probability of survival was 100% in both treatment groups after 1 year, but at the end of the 5-year follow-up period, this was significantly reduced to 98% and 96% in the GLP-1RA and non-GLP-1RA groups, respectively (log-rank test P value = .0001) (Figure 2 ). There were a total of 62 (13 vs 49) morality events with a crude incidence rate of 4.6 (2.0 vs 6.9) per 1,000 person-years in the GLP-1RA versus non-GLP-1RA groups, respectively. These are summarized in Table II .
Cardiovascular events. Among the 2,820 matched participants in the subgroup with no prior history of CV events, the probability of survival for the 2-point cardiovascular event of nonfatal MI and stroke fell from 99.5% and 99.3% after 1 year in the GLP-1RA versus non-GLP-1RA groups, respectively, to 97% in both groups at 5 years (log-rank test P value = .7880). Additionally, there were a total of 61 CV events, with an unadjusted crude incidence rate of 5.8 per 1,000 person-years with 28 and 33 events in the GLP-1RA versus non-GLP-1RA groups, respectively (crude incidence rates: 5.6 vs 6.0 per 1,000 person-years).
In the subgroup analysis for nonfatal MI, there were 7 events (3 vs 4 events in the GLP-1RA vs non-GLP-1RA groups, respectively [crude incidence rates: 0.6 vs 0.7 per 1,000 person years]). Similarly, a total of 25 versus 29 nonfatal stroke events were reported, signifying an unadjusted crude incidence rate of 5.0 vs 5.2 per 1,000 person-years (Table II) .
Risk of MACE, all-cause mortality, and composite cardiovascular outcomes
The summary of the hazard of MACE, all-cause mortality, and CV events between the treatment groups is presented in Table II Following adjustment for age, duration of diabetes and insulin use, gender, socioeconomic stats, alcohol use, estimated GRF (eGFR), lipid profile, and events of hypoglycemia, this was slightly reduced to 36% (adjusted hazard ratio (aHR): 0.64, 95% CI: 0.42-0.98).Similarly, the risk of all-cause mortality was 65% less (HR: 0.35, 95% CI: 0.17-0.73) in the GLP-1RA group following adjustment. Compared with the non-GLP-1RA group, the risk of composite cardiovascular outcomes was 24% less (aHR: 0.76, 95% CI: 0.41-1.42) in patients whose insulin therapy was intensified with GLP-1RA. Specifically, the risks of nonfatal MI and stroke were 38% and 7% nonsignificantly lower in the GLP-1RA group compared with the non-GLP-1RA group after adjustment for significant confounders (Table II) .
Glycemic control (change in HbA1c) and change in weight
Both treatment groups showed a significant reduction in HbA1c throughout the study period, but there was no significant difference between the groups at any of the study timelines (−0.32% vs −0.39%, P = .08 at 6 months; and −0.34% vs −0.41%, P = .33 at 36 months).
Conversely, there were significant increases in weight in both treatment groups in the first 6 months and up to 12 months in the non-GLP-1RA group. From 12 months in the GLP-1-RA group and 24 to 36 months in both groups, there were significant reductions in weight (Figure 3) . Between both treatment groups, there were significant differences of −0.37 kg and −0.57 kg in the mean weight recorded at 6 and 12 months, respectively. However, beyond 12 months, no significant differences in changes in weight were observed between the groups: −0.17 kg versus −0.55 kg (mean difference: −0.38 kg; P = .325) at 24 months and −0.99 kg versus −0.85 kg (mean difference: −0.13 kg; P = .768) at 36 months in the non-GLP-1RA vs GLP1-RA groups, respectively. subtypes-liraglutide, exenatide, and lixinatide. Compared with the insulin users who had no GLP-1RA add-on, the risk of MACE was 47% (aHR: 0.53; 95% CI: 0.32-0.89) and 19% (aHR: 0.81; 95% CI: 0.50-1.31) less in liraglutide and exenatide, respectively, whereas no event was recorded for lixinatide. Similarly, all-cause mortality was 83% (aHR: 0.17; 95% CI: 0.06-0.47) and 51% less (aHR: 0.49; 95% CI: 0.24-0.99), with no event for lixinatide. No difference was observed between the drug subtypes on CV events. Another sensitivity was conducted to explore the association between the intensification of insulin therapy with GLP-1RA versus none on hospitalizations for heart failure. There were 70 events of heart failure recorded (34 vs 36 events for the insulin alone vs insulin + GLP-1RA groups, respectively [3.7 vs 4.4 per 1,000 person-years; aHR: 1.22; 95% CI: 0.76-1.94; P = .415]) (Table II) . When stratified by the different subtypes of GLP-1RA, there were 15, 20, and 1 events of heart failure in exenatide, liraglutide, and lixisenatide, respectively, giving a crude incidence rate of 4.5 versus 4.4 versus 5.7 per 1,000 person-years. The risks of hospitalization for heart failure were 22%, 20%, and 66% nonsignificantly higher in exenatide, liraglutide, and lixisenatide, respectively compared with nonuse of GLP-1RA (Table III) .
Subgroup and sensitivity analyses
Further sensitivity analyses to compare the risks of the study outcomes in the full and matched cohorts showed no difference in the magnitudes of the effect sizes. Also, we compared the differences in change in HbA1c between both treatment groups using both complete and missing data and reported similar trend in both groups. This affirmed that the imputation robustly addressed the missing data.
Discussion
This study showed that, among overweight patients with insulin-treated T2D in routine clinical practice, adding a GLP-1RA was associated with a significant 36% risk reduction in a 3-point composite of all-cause mortality, nonfatal MI, and stroke; a 65% reduction in all-cause mortality; and a nonsignificant 24% reduction in CV events compared with no adjunctive GLP-1RA treatment. HbA1c reduction was similar between the 2 groups, whereas the use of GLP-1RA with insulin was associated with significant weight reduction compared with nonuse.
Our findings were similar in pattern with major clinical trials such as SUSTAIN-6 23 and LEADER. 16 In the LEADER trial, liraglutide (a GLP-1RA) was compared with placebo. Similar but smaller (13% and 15%) reductions in the risk of composite outcomes and all-cause mortality, respectively, were observed. These were replicated too in the SUSTAIN-6 trial. As shown in our study, the risks of nonfatal MI and nonfatal stroke were nonsignificantly lower as shown in these trials, but we reported a nonsignificant higher risk of hospitalization for heart failure in the GLP-1RA group which persisted for each type of GLP-1RA. Kaplan-Meier curves showing the 5-year probability of survival for all-cause mortality between INS ± GLP1-RA treatment groups. Log-rank test P value = .0001.
Evidence from RCTs has shown that the complementary mechanism of actions of GLP-1RA and insulin therapy offers a unique advantage to patients with T2D and is associated with significant reduction in HbA1c (meañ 0.8%) and in fasting and postprandial glucose, lower risk of hypoglycemia, prevention of weight gain, and concurrent reduction of insulin doses. [24] [25] [26] [27] It is conceivable that the weight reduction from GLP-1RA may be partly responsible for an increased effect of exogenous insulin delivered by insulin injections in study participants. However, the discrepancies in the HbA1c reduction observed in RCTs following the addition of GLP-1RA to insulin therapy compared with our neutral effect on HbA1c levels from real-world practice may reflect "real-life" patients' fear of hypoglycemia and weight gain, as well as the complexities of insulin dose reduction when adding a GLP-1RA to ongoing insulin therapy. Of note, most RCTs have used a treat-to-target design, where insulin doses were optimized by investigators simultaneous to adding a GLP-1RA. A previous study comparing the results from RCT and real-world studies on the efficacy of vildagliptin versus sulfonylureas, for example, showed that the decrease in HbA1c from baseline with sulfonylurea treatment is smaller in real life than in RCTs, whereas the reduction with vildagliptin is essentially the same, suggesting that the full power of treatment is retained in real life for vildagliptin but not for sulfonylureas, possibly due to fear of hypoglycemia. 28 Our observation of reduced composite of CV events and all-cause mortality when adding a GLP-1RA to insulin therapy, independent of HbA1c reduction, supports novel pleiotropic cardioprotective effects of GLP-1 agonist, which have been previously described. 13, 14 A further possible explanation for the observed reduction in the composite events with GLP-1RA could be due to the reduced risks of hypoglycemia as well as the beneficial effects of GLP-1 agonist in inducing weight loss-via the addition of a GLP-1RA and concurrent reductions in insulin doses. 17 Both hypoglycemia 29 and weight gain, 30 which are commonly associated with insulin therapy, are known risk factors for adverse CV events and mortality.
Insulin therapy has been known to induce weight gain. In contrast to evidence from RCT, where weight loss of between 0.4 and 1.8 kg was observed in the first 24-30 weeks of adding a GLP-1RA to insulin therapy, significant weight loss was only observed after 12 months of adding a GLP-1RA in routine clinical practice. At 24 months of follow-up, however, we observed a nonsignificant weight loss of −0.55 kg with adjuvant GLP-1RA compared with −0.17 kg without a GLP-1RA.The delay in weight response in this observational study may reflect in a delay in downtitration of insulin doses in routine clinical practice due to the lack of regular follow-up or a rigid treat-to-target treatment protocol. Of note, the baseline weight of our cohort is comparable with that from RCTs. The observed increase in body weight with insulin therapy (without adjuvant GLP-1RA) however is in conformity with previous studies. [24] [25] [26] [27] The main strength of our study derives from the inclusion of a large cohort of T2DM patients receiving insulin therapy in a real-world population which is largely representative of the UK population. This implies that our findings will be generalizable to various populations that share similar demographics. The large cohort of patients studied here provides adequate statistical power and also contains information on other time-varying covariates to adjust for possible confounders. We adjusted for a large set of factors that could have differed at the baseline through PS matching. This is crucial because the decision to add a GLP-1RA in routine clinical practice is often based on the fact that patients are overweight as per UK National Institute for Health and Care Excellence guidelines, 31 also confirmed by this study in Table I (where baseline weight in the full cohort [before matching] was significantly greater in the GLP-1RA group [96.6 kg vs 90.6 kg; P b .0001]). Nevertheless, some residual confounding in our study could persist due to our inability to measure and adjust for the dosage of the insulin therapy as well as the reliability of diabetes duration due to the ongoing issue of identifying incident versus prevalent diabetes. Also, the classification of exposure into 2 broad drug groups could have possibly masked the effects of individual drugs and could have driven our study away or closer to the null hypothesis. Finally, the low outcomes recorded in the subgroup analysis could be a reflection of poor recording or coding of these outcomes in the data set, although there were no validated data on the specific causes of mortality in the dataset.
In summary, the evidence from this large cohort study tracking outcomes in routine clinical practice suggests that adding a GLP-1RA as an adjunct to insulin therapy in overweight patients with T2D is associated with a significant reduction in a composite of all-cause mortality and CV events (MACE) and all-cause mortality, and a nonsignificant higher risk of hospitalization for heart failure compared with not adding a GLP-1RA therapy. The mechanism for these cardioprotective effects remained speculative, but further study in a randomized clinical trial setting is required to confirm this observation.
